156 related articles for article (PubMed ID: 24756789)
1. Lapatinib.
Nolting M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2014; 201():125-43. PubMed ID: 24756789
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib.
Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2010; 184():45-59. PubMed ID: 20072830
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
6. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
Abramovitz M; Williams C; Loibl S; Leyland-Jones B
Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
[TBL] [Abstract][Full Text] [Related]
7. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
8. An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H
Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
[TBL] [Abstract][Full Text] [Related]
9. [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Pikó B
Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
Sardesai SD; Storniolo AM
Womens Health (Lond); 2015 Jun; 11(3):281-94. PubMed ID: 26102468
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Friedecky D; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Dec; 154(4):281-8. PubMed ID: 21293538
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib and breast cancer: current indications and outlook for the future.
Moreira C; Kaklamani V
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1171-82. PubMed ID: 20735304
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
Kroep JR; Linn SC; Boven E; Bloemendal HJ; Baas J; Mandjes IA; van den Bosch J; Smit WM; de Graaf H; Schröder CP; Vermeulen GJ; Hop WC; Nortier JW
Neth J Med; 2010 Sep; 68(9):371-6. PubMed ID: 20876920
[TBL] [Abstract][Full Text] [Related]
15. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
16. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
17. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib in breast cancer: clinical experiences and future perspectives.
Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
[TBL] [Abstract][Full Text] [Related]
19. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
